Zymergen Inc. Research and Development Expense
Zymergen Inc. reported Research and Development Expense of $31.19 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-15
- Zymergen Inc. research and development expense for the quarter ending 2022-06-30 was $31.19M, a 37.82% decline year-over-year.
- Zymergen Inc. research and development expense for the quarter ending 2022-03-31 was $28.74M, a 27.81% decline year-over-year.
- Zymergen Inc. research and development expense for the quarter ending 2021-12-31 was $30.08M, a 0.73% increase year-over-year.
- Zymergen Inc. research and development expense for the quarter ending 2021-09-30 was $39.07M, a 80.04% increase year-over-year.
- Zymergen Inc. research and development expense for fiscal 2021 was $159.12M, a 75.14% increase from fiscal 2020.
- Zymergen Inc. research and development expense for fiscal 2020 was $90.85M, a 79.14% increase from fiscal 2019.
- Zymergen Inc. research and development expense for fiscal 2019 was $50.72M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $31.19M 10-Q · filed 2022-08-15 | $59.92M 10-Q · filed 2022-08-15 | $90.01M derived: sum of 3 quarters · filed 2022-08-15 | $129.08M derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | $28.74M 10-Q · filed 2022-05-12 | $58.82M derived: sum of 2 quarters · filed 2022-05-12 | $97.90M derived: sum of 3 quarters · filed 2022-05-12 | $148.05M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-12-31 | $30.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $69.16M derived: sum of 2 quarters · filed 2022-03-30 | $119.31M derived: sum of 3 quarters · filed 2022-08-15 | $159.12M 10-K · filed 2022-03-30 |
| 2021-09-30 | $39.07M 10-Q · filed 2021-11-15 | $89.22M derived: sum of 2 quarters · filed 2022-08-15 | $129.04M 10-Q · filed 2021-11-15 | $158.90M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-06-30 | $50.15M 10-Q · filed 2022-08-15 | $89.96M 10-Q · filed 2022-08-15 | $119.83M derived: sum of 3 quarters · filed 2022-08-15 | $141.53M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $39.81M 10-Q · filed 2022-05-12 | $69.68M derived: sum of 2 quarters · filed 2022-05-12 | $91.38M derived: sum of 3 quarters · filed 2022-05-12 | $108.86M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $29.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $51.57M derived: sum of 2 quarters · filed 2022-03-30 | $69.05M derived: sum of 3 quarters · filed 2022-03-30 | $90.85M 10-K · filed 2022-03-30 |
| 2020-09-30 | $21.70M 10-Q · filed 2021-11-15 | $39.18M derived: sum of 2 quarters · filed 2021-11-15 | $60.99M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $17.48M 10-Q · filed 2021-08-16 | $39.28M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $21.80M 10-Q · filed 2021-05-27 | |||
| 2019-12-31 | $50.72M 10-K · filed 2022-03-30 |